ESO-Shanghai 13: another milestone in the treatment of oligometastatic disease?
Alexander Grabenbauer,Tiuri E. Kroese,Matthias Guckenberger
DOI: https://doi.org/10.21037/cco-24-25
2024-08-07
Chinese Clinical Oncology
Abstract:Alexander Grabenbauer , Tiuri E. Kroese * , Matthias Guckenberger * Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland * These authors contributed equally to this work as co-last authors. Comment on: Liu Q, Chen J, Lin Y, et al . Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2024;9:45-55. Keywords: Squamous cell esophageal cancer; oligometastatic disease; local ablative therapy Submitted Feb 26, 2024. Accepted for publication Jun 19, 2024. Published online Aug 01, 2024. doi: 10.21037/cco-24-25 Esophageal cancer is the eighth most common cancer worldwide and the sixth most common cause of cancer death worldwide (1). Esophageal carcinomas can be subdivided into two histological subtypes, adenocarcinoma, and squamous cell carcinoma. The less common adenocarcinoma is mainly associated with the risk factor of Barrett's esophagus, whereas squamous cell carcinoma is mainly associated with smoking and the consumption of hard alcohol (2). Depending on the stage, the current treatment of early-stage squamous esophageal carcinoma consists of surgical resection alone. Treatment for locally advanced disease consists of neoadjuvant chemoradiotherapy followed by resection or definitive radiochemotherapy. Adjuvant immunotherapy is applied if after (salvage) resection residual vital tumor is present in the resection specimen (3,4). The standard-of-care for metastatic cancer is palliative systemic therapy. However, patients with limited metastatic disease (so-called oligometastatic disease) might benefit from metastasis-directed therapy in addition to standard-of-care systemic therapy (5,6). The aim of local therapy for oligometastatic disease is to eradicate metastatic lesions and to render the patient disease-free, if patients are free from microscopic disease or if microscopic disease is controlled by systemic therapy (7). Accordingly, this treatment approach was assessed in the ESO-Shanghai 13 study. In the ESO-Shanghai 13 study (8), 116 patients, aged at least 18 years old with an Eastern Cooperative Oncology Group (ECOG) 0–1, and a histological confirmation of oligometastatic squamous cell carcinoma of the esophagus were included between March 2019 and September 2021. Further inclusion criteria were a controlled primary tumor by surgery or radiotherapy with no progression ≤3 months. Oligometastatic disease was defined ≤4 metastatic lesions in ≤3 different organs and a diameter of ≤5 cm. All metastatic lesions were required to be amenable to local therapeutic intervention without having undergone prior treatment. Important exclusion criteria were the receipt of antitumor medication within 3 months or history of widespread metastases. In total, 104 patients were randomized 1:1 to standard-of-care systemic therapy alone or systemic and local therapy. Randomization was balanced on the three prognostic covariates number of disease sites (one vs. two to four), the lines of systemic therapy (first-line vs. second-line) and the location of the metastases (non-regional nodes alone vs. visceral metastases). The systemic therapy in both groups consisted of four cycles of standard-of-care chemotherapy and after an amendment in July 2020 optional immunotherapy with anti-PD-1 antibody. Immunotherapy in first- and second-line treatment was administered to 20 of 53 patients in the systemic and local therapy group, whereas 23 of 51 patients in the systemic therapy alone group received immunotherapy. The preferred local therapy with 89% was radiotherapy with stereotactic ablative body radiotherapy (SABR) being used in 38% of the patients, conventional fractionated intensity-modulated radiotherapy in 47% patients and hypofractionated radiotherapy in 4% of the patients. SABR was commonly applied with ≤5 fractions of ≥7 Gy, whereas conventional radiotherapy was performed using involved-field irradiation and a prescribed dose of at least 45–66 Gy with 1.8–2.0 Gy per fraction. For all lesions not amenable to SABR, local treatment options were conventional radiotherapy, surgery, or thermal ablation. Local lesions in the systemic therapy only group could only be treated in the event of progression, for symptom relief or as palliative radiotherapy otherwise the patient would be censored at the time of crossover. The primary endpoint of the study was progression-free survival (PFS), while prespecified secondary endpoints were overall survival (OS), proportion of patients with local control, toxicity, and the quality of life. The study demonstrated that the systemic and local therapy cohort had superior outcomes compared to the systemic therapy-only cohort. This was shown by improved PFS of 15.3 months in the systemic and loca -Abstract Truncated-